Vivos Therapeutics, Inc. Form 8-K Filing

Vivos Therapeutics, Inc. has filed a Form 8-K detailing significant executive changes and agreements. Bradford Amman has resigned as Chief Financial Officer and Secretary, effective July 31, 2026. He will remain with the company as a non-executive transition employee for 90 days, serving as principal accounting officer, followed by a 180-day advisory role as an independent contractor. His separation agreement includes continued salary during the transition, a monthly advisory fee, COBRA premium payments, and a stock award of 250,000 shares along with an option to purchase 150,000 shares, subject to board approval and a potential equity financing. Concurrently, Roman Franklin has been appointed as the new Chief Financial Officer, effective July 31, 2026. He will serve through a Master Services Agreement with The CFO Portal, LLC, providing managed CFO and finance leadership services. Franklin brings over 20 years of experience. The agreement includes an annual retainer of $324,000 and an equity award valued at approximately $237,360. Franklin will also be granted a stock option to purchase 552,000 shares, vesting over twelve months, with accelerated vesting upon certain termination events.